Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL0020
- Development stage
- Phase 2
- Lead developer
- Shanghai Best-Link Bioscience
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
BL0020 is a novel anti-tumor drug currently in Phase I clinical development for the treatment of advanced solid tumors, including triple-negative breast cancer, small cell lung cancer, and pancreatic cancer. It is being developed by Shanghai Best-Link Biosciences. The drug is administered intravenously and is classified as an antineoplastic agent. Its precise mechanism of action has not been disclosed or defined in public sources as of the latest updates. The primary objectives of ongoing trials are to evaluate its safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in adult patients with advanced solid tumors[1][2][3][4][5].
Beyond the preview
Go deeper on BL0020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL0020.